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Bone marrow derived myeloid cells progressively accumulate in tumors, where they establish an inflammatory
microenvironment that is favorable for tumor growth and spread. These cells are comprised primarily of monocytic
and granulocytic myeloid derived suppressor cells (MDSCs) or tumor-associated macrophages (TAMs), which are
generally associated with a poor clinical outcome. MDSCs and TAMs promote tumor progression by stimulating
immunosuppression, neovascularization, metastasis and resistance to anti-cancer therapy. Strategies to target the
tumor-promoting functions of myeloid cells could provide substantial therapeutic benefit to cancer patients.
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Chronic inflammation is a causative or exacerbating fac-
tor in a host of complex human diseases, including solid
tumors and leukemias/lymphomas, chronic bacterial and
parasitic infections, rheumatoid arthritis, Crohn’s dis-
ease, asthma and central nervous system (CNS) disor-
ders such as Alzheimers’ disease, Parkinson’s disease and
multiple sclerosis. In each of these diseases, affected tis-
sues are heavily invested with inflammatory myeloid
cells, which include resident or bone marrow derived
macrophages [1-4]. In addition, all tumors are heavily
invested with myeloid cells, including tumor-associated
macrophages (TAMs) [5,6]. Myeloid cells stimulate can-
cer initiation, malignant progression, metastasis and
resistance to therapy [7]. Thus, targeting molecular path-
ways regulating the tumor promoting functions of mye-
loid cells holds promise for solid tumor therapy.Macrophages in normal and tumor biology
Macrophages are myeloid lineage cells that arise from
bone marrow derived monocytic progenitor cells that
differentiate into tissue macrophages, antigen-presenting
dendritic cells and bone resorbing osteoclasts [8,9].
Macrophages can be activated in response to environ-
mental signals, including microbial products and cyto-
kines. Activated macrophages can be loosely divided into
M1 (classically activated) and M2 (alternatively activated)* Correspondence: jvarner@ucsd.edu
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distribution, and reproduction in any mediumphenotype [1]. Classical activation occurs in response to
bacterial moieties such as lipopolysacharide (LPS) and
immune stimuli such as interferon γ (IFNγ). M1 macro-
phages mediate resistance against intracellular parasites
and tumors and elicit tissue disruptive reactions by se-
creting tumoricidal agents such as tumor necrosis factor
α (TNF-α), interleukin-12 (IL-12), and reactive nitrogen
and oxygen intermediates (RNI, ROI). In addition, M1
macrophages promote T-helper-l (Thl) responses. In gen-
eral, M2 macrophages exhibit an immunosuppressive
phenotype and release factors that include IL-l0 and
Arginase-1 [10,11].
M2 macrophages are the predominant type of macro-
phage found in tumors [6]. M1 macrophages are abun-
dant at sites of chronic inflammation and in early
tumors [12,13], but then switch to an M2-like phenotype
during tumor progression [14-16]. Although IL-4, IFNγ,
and several other tumor-derived cytokines and growth
factors modulate macrophage phenotypes in vitro and
in vivo [1,17], the molecular mechanisms that promote
M1 or M2 TAM subsets within the tumor microenvir-
onment are incompletely understood.
Although TAMs can convert into M1 or M2 pheno-
types, and thereby execute almost diametrically opposed
biological functions, unique cell surface markers that
distinguish the two TAM phenotypes remain elusive. Flow
cytometric analysis does indicate that M1-like TAMs
express an F4/80 +CD11c+MRClow phenotype, while
M2-like TAMs express an F4/80 +CD11cnegMRChigh phe-
notype [18].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Myeloid derived suppressor cells (MDSC) are CD11b+Gr1+
immunosuppressive, incompletely differentiated myeloid
progenitor cells originally identified in tumor bearing
mice [19]. MDSC accumulate in the blood, spleen, lymph
nodes, bone marrow and tumors of tumor-bearing ani-
mals and patients [20-24]. MDSCs inhibit innate and
adaptive immunity, promoting tumor immune escape.
MDSC are a heterogeneous population of cells that lack
the expression of cell surface markers that are specifically
expressed on macrophages or DC [25]. In mice, MDSC
are uniformly characterized by the expression of Gr1 and
CD11b. Gr1 includes the macrophage and neutrophil
markers Ly6C and Ly6G, respectively, whereas CD11b
(also known as integrin αM) is characteristic for the
myeloid- cell linage. In recent years, several other surface
molecules have been used to identify additional subset of
immunosuppressive MDSC, including CD80 [26], CD115
(also known as macrophage colony stimulating factor
(M-CSF) receptor) and CD124 (IL-4 receptor alpha
chain, IL-4Rα) [27]. In addition, nuclear morphology has
also been used to characterize mouse MDSC. Mono-
nuclear CDllb+Gr1midLy6G+/−Ly6ChighCD49d+ cells are
considered “monocytic” whereas polymorphonuclear
CDllb+Gr1highLy6G+Ly6CnegCD49dneg MDSC are con-
sidered granulocytic [28-30]. Subpopulations of MDSC
can give rise to CD11b+Gr1lowF4/80+MHCII+ macro-
phages with potent immunosuppressive properties, under-
scoring the potential biological continuum of immature
myeloid cells, monocytes, and macrophages [20,25,31].
In patients with glioblastoma, breast cancer, colon
cancer, lung cancer or kidney cancer, MDSC have been
defined as LinnegCDllb+HLA-DRnegCD33+ cells that ex-
press the common myeloid marker CD33 but lack
mature monocyte and lymphoid cell linage markers
(Linneg = CD14neg, CD3neg, CD19neg) and lack the MHC
class II molecule HLA-DR [32]. In patients with renal
cancer, polymorphonuelcar MDSC have been shown to
express CD11b+ CD14negCD15+CD66b+ VEGFR1+ [33]
whereas in patients with melanoma, prostate cancer,
hepatocellular carcinoma or head and neck cancer,
immunosuppressive monocytic CD11b+ CD14+ HLA-
DRlow/neg MDSC were found [21,34-36]. These cells
are associated with increased tumor burden and poor
prognosis in patients with breast and colorectal can-
cer [24,37].
Mechanisms of myeloid cell recruitment
Immune cell trafficking in vivo is regulated by chemo-
kines and cytokines, and by members of the integrin, im-
munoglobulin and selectin adhesion molecule families
[38,39]. A diverse array of chemotactic factors that are
expressed either by tumor cells or tumor infiltrating
immune cells stimulate myeloid cell recruitment intotumors. These factors include CCL2 (MIP-1), CCL5
(RANTES), CCL12, IL-8, IL-lβ, CXCL12 (SDF-1α), and
CXCL5 (ENA-78) [40-44].
While malignant tumor cells express myeloid cell che-
moattractants, tumor infiltrating immune cells also ex-
press a variety of chemotactic factors, which can further
foster myeloid cell recruitment and accumulation in the
tumor microenvironment. For example, myeloid cell
derived IL-1β stimulates myeloid cell recruitment in vivo
and pharmacological inhibition of IL-1β reduced the in-
filtration of myeloid cells into the tumor microenviron-
ment and inhibited tumor progression in a lung cancer
tumor model [42]. Tumor derived factors, such as G-
CSF, can also stimulate long-range effects in the bone
marrow, leading to myeloid cell expression of Bv8, a fac-
tor that stimulates myelopoiesis and mobilization [45,46].
Recent efforts have also been made to identify tumor-
derived factors that specifically recruit myeloid cells in
response to chemotherapeutic treatments. CCL2 and
CCL12 were highly upregulated in doxorubicin treated
MMTV-PyMT animals; genetic depletion of CCR2 or
pharmacological blockade of GPCR-mediated signaling
with pertussis toxin, reduced myeloid cell recruitment in
response to chemotherapy and increased the sensitivity
of tumors [41]. Paclitaxel treatment of MMTV-PyMT
animals induced colony stimulating factor 1 (CSF-l) and
IL-34 expression, which together stimulated CSF1 re-
ceptor (CSF1R)-dependent macrophage infiltration [47].
Blockade of CSF1R signaling in combination with pacli-
taxel improved survival of mammary tumor-bearing
mice. Myeloid cells thus play a central role in resistance
to chemotherapy.
Roles of integrins in myeloid cell recruitment
The integrin adhesion molecule family is an extensive
group of structurally related receptors for extracellular
matrix (ECM) proteins and immunoglobulin superfamily
molecules. Integrins are divalent cation-dependent het-
erodimeric membrane glycoproteins comprised of non-
covalently associated α and β subunits that promote cell
attachment and migration on the surrounding extracel-
lular matrix. Eighteen α and eight β subunits can associ-
ate to form twenty-four unique integrin heterodimers
[48,49]. Integrins on bone marrow-derived immune cells
promote tumor inflammation by facilitating myeloid cell
trafficking to the tumor microenvironment [42,50,51].
Myeloid cells express a number of functional integrins,
including α2β1, α4β1, α5β1, αvβ3, αvβ5, αMβ2 (CD11b)
and αXβ2 (CD11c) [52-54]. Recent studies from our la-
boratory indicate that integrin α4β1, a receptor for vas-
cular cell adhesion molecule 1 (VCAM-1) and CS-l
fibronectin, selectively promotes the homing of myeloid
cells to the tumor microenvironment [42,55]. Human
and murine myeloid cells adhered to endothelial cells
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α4β1. Genetic and pharmacological blockade of integrin
α4βl significantly suppressed tumor inflammation, growth
and metastasis. In addition, combination of anti-integrin
α4 antibody and chemotherapeutic agents markedly
reduced tumor burden compared to chemotherapeutic
treatment alone [42]. Thus, these studies indicate that
suppression of myeloid cell trafficking to the tumor
microenvironment with integrin α4βl antagonists could
be a useful adjuvant approach in cancer therapy.
Signaling molecules in myeloid cell recruitment
Integrins are expressed in an inactive confirmation on
circulating immune cells [49,56,57]. Inflammatory fac-
tors released by tissues activate G protein coupled re-
ceptors (GPCRs), receptor tyrosine kinases (RTKs) or
Toll-like receptor/interleukin1 receptor family members
(TLR/IL1Rs), which initiate myeloid cell recruitment
during inflammation [50]. We recently demonstrated
that PI3Kγ promotes inflammation downstream of di-
verse receptors by stimulating inside-out activation of
integrin, α4β1, granulocytic and monocytic cell adhesion
to endothelium and invasion into tumors [51]. Pharma-
cological or genetic blockade of PI3Kγ suppressed adhe-
sion and recruitment of monocytic and granulocytic
cells into inflamed tissues. These findings suggested that
targeting the trafficking of myeloid cells into tumors
might provide significant benefit in the treatment of a
wide variety of diseases. While all the steps in integrin
activation have yet to be deciphered, PI3Kγ activates the
small GTPase, Rap1, which promotes talin binding to in-
tegrin β1− subunit cytoplasmic domains, thereby indu-
cing a shift in the conformation of the extracellular
domain of the integrin and increasing ligand binding af-
finity [58,59]. In addition, paxillin binding to the α4
cytoplasmic tail enhances integrin α4 activation, as dis-
ruption of the paxillin binding site in the integrin α4
cytoplasmic tail partially prevents talin binding and inhi-
bits adhesion under flow in vitro and in vivo (Figure 1)
[42,60,61].
Roles of myeloid cells in tumor progression
Angiogenesis
MDSC and TAMs play major roles in vascular remod-
eling during tumor progression. MDSC and TAMs re-
lease a number of potent pro-angiogenic cytokines, such
as VEGF-A, VEGF-C, TNF-α, Placenta derived growth
factor β (PlGF), chemokines (CXCL12, CXCL8), and
bFGF [62,63]. TAMs also express a broad array of pro-
teases known to play roles in the angiogenic process, in-
cluding urokinase-type plasminogen activator (uPA), the
matrix metalloproteinases MMP-2, MMP-7, MMP-9 and
MMP-12 and elastase [64,65]. uPA and MMP support
angiogenesis by remodeling and breaking down theextracellular matrix (ECM). Degradation of ECM leads
to the mobilization of growth factors and facilitates
the migration of vascular cells into new environments
[66,67] (Figure 2c).
Immune suppression
MDSC and TAMs are both major regulators of the im-
mune response [2].
MDSC suppress T cell proliferation in part by expres-
sion of Arginase-1 [68]. L-arginine plays a critical role in
the inhibition of cytotoxic T cells by MDSC. Arginase
converts L-arginine into L-ornithine and urea, thereby
depleting L-arginine from the microenvironment and
preventing iNOS from converting L-arginine to NO, an
immunostimulant [69]. Depletion of arginine by Argi-
nase I inhibits expression of the T-Cell Receptor (TCR)
CD3zeta chain and T cell proliferation [70]. MDSC pro-
duced ROS also inhibits CD8+ T cell function by catalyz-
ing the nitration of the TCR and thereby preventing T
cell peptide-MHC interactions [71]. Moreover, several
known tumor-derived factors, such as TGF-β, IL-3, IL-6,
IL-l0, Platelet derived growth factor β, and granulocyte
macrophage colony stimulating factor (GM-CSF) can in-
duce the production of ROS by MDSC [8,72].
Beside inhibition of T cell activation, MDSC secrete
immune suppressive cytokine with can inhibit immune
surveillance. Secretion of the type 2 cytokine IL-l0
down-regulates the production of the type 1 cytokine
IL-12 in macrophages. In addition, IL-l0 and VEGF-A
inhibit the maturation of DC [68]. TGF-β has also been
associated with MDSC immune suppressive functions.
In fibrosarcoma and colon carcinoma tumor models,
MDSC produced TGF-β in response to IL-13 stimula-
tion, which resulted in decreased tumor immunosurveil-
lance of cytotoxic T –cells [73,74].
Myeloid cells in relapse or resistance to therapy
CD11b+Grl+ myeloid cells and TAMs play key roles in
regulating the response of tumors to therapy, including
anti-angiogenic and chemotherapeutic treatments. Accu-
mulation of CD11b+Grl+ cells in tumors inhibits respon-
siveness to anti-angiogenic blockade by anti-VEGF-A
antibodies [75]. Bv8, a protein expressed by myeloid cells
in the bone marrow, stimulated the expansion and
mobilization of CD11b+Grl+ cells in the bone marrow
and mediated resistance to anti-VEGFA therapy [76,77].
Macrophages and anti-cancer therapy
The significance of the vascular remodeling functions
of TAMs in cancer therapy has recently emphasized
by several studies. Tumor blood vessels are mostly dis-
organized and immature compared to non-pathological
angiogenesis. Blood vessels are more torturous, with






























Figure 1 Mechanisms regulating the recruitment of myeloid cells to the tumor microenvironment. (a) Myeloid cells are activated and
mobilized from the bone marrow in response to tumor derived factor such as Bv8, SDF-1α, GM-CSF. (b) Circulating myeloid cells express integrin
adhesion molecules in an inactive confirmation, with low binding affinity. (c) In response to diverse chemotactic factors released from the tumor
microenvironment, myeloid PI3Kγ activates the adhesion molecule integrin α4β1. (d) Myeloid cells are now able to bind to the activated tumor
endothelium expressing the integrin α4β1 ligand VCAM-1. (e) Myeloid cells extravasate from the blood stream and migrate toward the tumor
microenvironment, (f) where they differentiate in response to the cytokines/chemokine milieu to tumor associated macrophages. Px, Paxillin; Tn,
Talin; TAM, tumor associated macrophages.
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normalization can be modulated by targeting the
angiopoietin/Tie2 pathway. Interestingly, the angiopoie-
tin receptor Tie2 is not only expressed on endothelial
cells, but also a subpopulation of tumor infiltrating
macrophages with vascular remodeling function. Tar-
geting the Angiopoietin/Tie2 pathway by a fully huma-
nized anti-ANG2 monoclonal antibody inhibited tumor
angiongenesis, growth, and metastasis, and disabled the
pro-angiogenic functions of tumor infiltrating macro-
phages, thus impeding the emergence of evasive resist-
ance to anti-angiogenic therapy [79]. Genetic depletion
of VEGF-A gene under the macrophage specific pro-
moter LysM-Cre attenuates tumor angiogenesis and
results in a morphologically more normal vasculature___.
Tumors with normalized blood vessels showed increasedsensitivity to chemotherapeutic treatment [80]. Similarly,
histidine-rich glycoprotein HRG, a host-produced pro-
tein deposited in tumor stroma, can induce a reprogram-
ming of the vascular remodeling functions of TAMs,
resulting in vascular normalization and improved re-
sponses to chemotherapy [18]. In another report, block-
ade of CSF-1 signaling in a breast cancer tumor model,
resulted in reduced numbers of intra-tumoral macro-
phage, normalized tumor vasculature, and increased
responses to chemotherapy [47]. Notably, beside vascular
normalization, both studies also showed enhanced anti-
tumor immune responses, thus indicating the complexity
of crosstalk’s by diverse cell types within the tumor
microenvironment, and the power of targeting one sub-
type to thereby subvert biological functions of other stro-
mal cells.
• secretion of angiogenic factors:
VEGF-A, PlGF, IL-8, bFGF
• secretion of ECM remodelling proteases: 
MMPs, uPA
• Secretion of immune suppressive  
factors: Arginase-1, IL-10, TGF- , ROS
• Recruitment of regulatory T cells: CCL22
• expression of immune suppressive 
surface mediators: B7-family proteins
• Secretion of pro-inflammatory factors:
TNF- , IL12 , IFN
• Secretion of mutagenic factors:
RNI, ROI
• Efficient antigen presentation
• Tumor destruction and 
tissue damage
• Secretion of ECM degrading 
proteases : MMPs, uPA, Cathepsins
• Secretion of pro-invasive factors: EGF
• Establishment of a metastatic niche
• Survival signals for disseminated 
cancer  cells (integrin 4 1)
Figure 2 Diverse roles of TAMs in the tumor microenvironment. TAMs are critical regulator of tumor initiation and progression. (a)
Inflammatory TAMs can initiate a chronic smoldering inflammation that creates a mutagenic and growth-promoting environment. (b) In
established tumors, immune suppressive TAMs secrete factors which inhibit the activation of cytotoxic T cells and promotes the recruitment of
regulatory T cells. (c) Pro-angiogenic TAMs stimulate the formation of new blood vessels by secreting angiogenic growth factors and ECM
remodeling proteases. (d) TAMs support invasion and metastasis of malignant cells by destructing the ECM though proteases, by secreting
invasion-inducing factors, and by supporting the establishment of a pro-metastatic niche. ROI, reactive oxygen intermediates; RNI, reactive
nitrogen intermediates; ECM, extracellular matrix.
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was proposed by Johanna Joyce and colleagues. The
authors identified that TAMs secreted factors that pro-
tect tumors from chemotherapy. In the PyMT breast
cancer models, tumors treated with the chemotoxic
agent paclitaxel had more TAMs than control tumors.
These TAMs expressed increased levels of proteases,
specifically cysteine cathepsin B. Expression of cathepsin
B was suggested to be necessary to protect cancer cells
in vitro and in vivo from several chemotoxic agents, in-
cluding paclitaxel, etoposide, and doxorubicin [81].
Conclusions
Myeloid cells promote tumor progression and alter the
response of tumors to anti-cancer therapies. Identifica-
tion and targeting of myeloid cells represents an emer-
ging and attractive therapeutic approach to fight cancer.
Therapeutic strategies targeting TAMs include inhibition
of their recruitment to the tumor microenvironment,
blockade of their pro-tumoral effector functions, and re-
programming of macrophage/MDSC polarization and
thus restoring their anti-tumorigenic functions. Target-
ing myeloid cell recruitment can reduce tumor progres-
sion and improve the efficacy of chemotherapeutictreatments [41,51]. Similarly, partial reprogramming of
macrophage polarization towards an M1-like phenotype
enhances chemotherapy and reduces tumor growth
[18,82]. Importantly, some of the anti-tumorigenic func-
tions of macrophages critically depend on the presence
of cytotoxic CD8+ T-cells, which are part of the adaptive
immune system [47,83].
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